Related Experiment Video
Updated: Jun 17, 2026
08:30
Isolation of Group 2 Innate Lymphoid Cells from Mouse Nasal Mucosa to Detect the Expression of CD226
Published on: May 10, 2022
Soluble CD26 levels and its association to epidemiologic parameters in a sample population
Loretta De Chiara1, Ana M Rodríguez-Piñeiro, Oscar J Cordero
1Universidad de Vigo, Facultad de Biología, Departamento de Bioquímica, Genética e Inmunología, As Lagoas-Marcosende s/n, 36310 Vigo, Spain.
Disease Markers
|January 16, 2010
Summary
Soluble CD26 (sCD26) shows potential as a colorectal cancer marker. While not linked to CRC history or common symptoms, sCD26 levels correlate with certain benign inflammatory and non-inflammatory pathologies.
Area of Science:
- Oncology
- Biochemistry
- Clinical Diagnostics
Background:
- Soluble CD26 (sCD26) has been investigated as a potential tumor marker for colorectal cancer (CRC) and advanced adenomas.
- Previous studies indicated sCD26's utility, prompting further investigation in a larger cohort.
Purpose of the Study:
- To assess sCD26 concentration in a large cohort.
- To evaluate the association between sCD26 levels and epidemiological parameters.
- To determine the relationship between sCD26 and CRC-related symptoms or pathologies.
Main Methods:
- Serum samples were collected from 2,754 healthy individuals aged 30-65.
- Participants had a personal or familial history of polyps, CRC, or colorectal symptoms.
- sCD26 levels were quantified using enzyme-linked immunosorbent assay (ELISA).
Main Results:
- No significant association was found between sCD26 levels and age, personal/familial history of polyps or CRC, rectal bleeding, hemorrhoids, or diverticula.
- sCD26 concentration was found to be related to non-inflammatory benign pathologies (excluding specific symptoms).
- sCD26 levels also showed a correlation with inflammatory benign pathologies.
Conclusions:
- The study confirms that sCD26 can be readily measured in large populations.
- Further validation is needed to establish sCD26 as a reliable tumor marker for screening.
- Comparison with established non-invasive tests, such as fecal occult blood testing, is recommended for sCD26 validation.
